OCUP - Ocuphire eye drop Nyxol for reversing pupil dilation meets main goal in 2nd phase 3 trial

Ocuphire Pharma (NASDAQ:OCUP) said a second late stage study of its eye drop Nyxol for reversing pharmacologically-induced dilation of pupil (mydriasis), met its main goal. The phase 3 trial, dubbed MIRA-3, enrolled 368 people (336 adults and 32 adolescents at or over age 12) who received either Nyxol (0.75% phentolamine ophthalmic solution) or vehicle control (placebo) one hour after receiving one of 3 mydriatic agents, which are used to dilate pupils for eye exams and in surgical procedures. The study met its main goal with 58% of people (study eye) treated with Nyxol returning to ? 0.2 mm of their baseline pupil diameter (PD) at 90 minutes compared to 6% of people (study eye) receiving placebo. The study also met key secondary goal, which included, onset of action with 42% of people at baseline PD by 60 minutes post-dose compared to 2% on placebo. The company added that significantly more Nyxol-treated people returned

For further details see:

Ocuphire eye drop Nyxol for reversing pupil dilation meets main goal in 2nd phase 3 trial